Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

NCT03999515 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Terminated due to slow accrual

Conditions

Castration-Resistant Prostate Carcinoma
Double-Negative Prostate Carcinoma
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG: Abiraterone Acetate
DRUG: Enzalutamide
DRUG: Erdafitinib

Sponsor

University of Washington

Collaborators

[object Object]